全球未分级肝素市场规模、份额、趋势和成长分析报告（2026-2034年）

预计到 2034 年，未分级肝素市场规模将从 2025 年的 13.4 亿美元成长至 24.1 亿美元，2026 年至 2034 年的复合年增长率为 6.68%。

由于未分级肝素在抗凝血治疗中发挥至关重要的作用，且临床应用广泛，预计其全球市场将稳步成长。儘管低分子量肝素製剂的应用日益增多，但未分级肝素在心血管手术、透析和体外循环中仍然不可或缺。其起效迅速且作用可逆，使其成为首选药物，尤其是在加护病房(ICU) 等需要病患病情稳定的急诊医疗环境中。随着新兴经济体医疗基础设施的不断完善，对经济有效的抗凝血剂的需求预计将保持强劲，从而推动市场成长。

肝素萃取和纯化技术的进步正在提高产品品质和安全性，最大限度地减少肝素诱发的血小板减少性疾病不利事件。此外，对合成和重组生产过程的持续研究有望减少对猪源性原料的依赖，并解决供应链脆弱性和伦理问题。这些创新可望在确保符合严格监管要求的同时，树立生产效率的新标准。这些进展不仅将增强供应稳定性，还将为高品质肝素製剂开闢新的机会。

该市场的未来趋势将受到全球心血管疾病和血栓性栓塞症负担日益加重的显着影响。此外，外科手术和透析治疗数量的不断增长也凸显了对可靠抗凝血剂的持续需求。市场参与企业正积极投资于后向整合、合作研究和地理扩张，以保持其长期竞争力。加之政府对改善基本药物可近性的支持，预计未分级肝素将继续在挽救生命的治疗通讯协定中发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球未分级肝素市场：依来源划分

• 市场分析、洞察与预测
• 源自牛
• 源自猪

第五章：全球未分级肝素市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第六章 全球未分级肝素市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Becton
  • Dickinson And Company
  • BioMAfA（C）Rieux SA
  • Bio-Rad Laboratories Inc
  • Eiken Chemical Co. Ltd
  • Merck Millipore（EMD Millipore）
  • HiMedia Laboratories Pvt. Ltd
  • Neogen Corporation
  • Sigma-Aldrich Co. LLC
  • Scharlab SL
  • Thermo Fisher Scientific Inc

The Unfractionated Heparin Market size is expected to reach USD 2.41 Billion in 2034 from USD 1.34 Billion (2025) growing at a CAGR of 6.68% during 2026-2034.

The global unfractionated heparin market is poised for steady growth, driven by its critical role in anticoagulation therapy and broad clinical applications. Despite the rising adoption of low-molecular-weight alternatives, unfractionated heparin continues to be indispensable in cardiovascular surgeries, dialysis procedures, and extracorporeal circulation. Its rapid onset of action and reversibility make it a preferred choice in acute care environments, particularly in intensive care units where patient stability is paramount. With expanding healthcare infrastructure across emerging economies, the demand for cost-effective anticoagulants is expected to remain resilient, supporting market expansion.

Technological advancements in heparin extraction and purification methods are enhancing product quality and safety, thereby minimizing adverse events such as heparin-induced thrombocytopenia. Moreover, ongoing research into synthetic and recombinant production processes could reduce dependency on porcine sources, addressing both supply chain vulnerabilities and ethical concerns. These innovations are likely to establish new benchmarks in production efficiency while ensuring compliance with stringent regulatory standards. Such developments not only strengthen supply security but also open new opportunities for premium-grade heparin formulations.

The future trajectory of this market will be strongly influenced by the rising global burden of cardiovascular and thromboembolic disorders. Additionally, the increasing volume of surgical procedures and dialysis sessions underscores the persistent need for reliable anticoagulants. Market participants are strategically investing in backward integration, collaborative research, and geographical expansion to sustain long-term competitiveness. With supportive government initiatives to improve accessibility to essential medicines, unfractionated heparin is expected to remain a cornerstone in life-saving therapeutic protocols.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Source

• Bovine
• Porcine

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Becton, Dickinson and Company, bioMrieux SA, BioRad Laboratories Inc, Eiken Chemical Co Ltd, Merck Millipore EMD Millipore, HiMedia Laboratories Pvt Ltd, Neogen Corporation, SigmaAldrich Co LLC, Scharlab SL, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL UNFRACTIONATED HEPARIN MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Bovine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Porcine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL UNFRACTIONATED HEPARIN MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL UNFRACTIONATED HEPARIN MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Source
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Source
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Source
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Source
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Source
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL UNFRACTIONATED HEPARIN INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Becton
  • 8.2.2 Dickinson And Company
  • 8.2.3 BioMAfA(C)Rieux S.A
  • 8.2.4 Bio-Rad Laboratories Inc
  • 8.2.5 Eiken Chemical Co. Ltd
  • 8.2.6 Merck Millipore (EMD Millipore)
  • 8.2.7 HiMedia Laboratories Pvt. Ltd
  • 8.2.8 Neogen Corporation
  • 8.2.9 Sigma-Aldrich Co. LLC
  • 8.2.10 Scharlab S.L
  • 8.2.11 Thermo Fisher Scientific Inc